Literature DB >> 21685372

Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes.

Wai-Hong Tham1, Christoph Q Schmidt, Richard E Hauhart, Mara Guariento, Patience B Tetteh-Quarcoo, Sash Lopaticki, John P Atkinson, Paul N Barlow, Alan F Cowman.   

Abstract

The Plasmodium falciparum adhesin PfRh4 binds to complement receptor type-1 (CR1) on human erythrocytes and mediates a glycophorin-independent invasion pathway. CR1 is a complement regulator and immune-adherence receptor on erythrocytes required for shuttling of C3b/C4b-opsonized particles to liver and spleen for phagocytosis. Using recombinant CR1 constructs, we mapped the recognition site for PfRh4 to complement control protein modules 1 to 3 (CCP1-3) at the membrane-distal amino terminus of CR1. This region of CR1 binds to C4b and C3b and accelerates decay of both classic pathway and alternative pathway C3 and C5 convertases. CCP1-3 competed for PfRh4 binding to erythroid CR1 and inhibited the PfRh4-CR1 invasion pathways across a wide range of P falciparum strains. PfRh4 did not bind significantly to other CR1 constructs, including CCP15-17, which is 85% identical to CCP1-3. PfRh4 binding to CR1 did not affect its C3b/C4b binding capability, and we show evidence for a ternary complex between CCP1-3, C4b, and PfRh4. PfRh4 binding specifically inhibited CR1's convertase decay-accelerating activity, whereas there was no effect on factor H-mediated decay-accelerating activity. These results increase our understanding of the functional implications of CR1 engagement with PfRh4 and highlight the interplay between complement regulation and infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685372      PMCID: PMC3158720          DOI: 10.1182/blood-2011-03-341305

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Invasion profiles of Brazilian field isolates of Plasmodium falciparum: phenotypic and genotypic analyses.

Authors:  Cheryl-Ann Lobo; Karla de Frazao; Marilis Rodriguez; Marion Reid; Mariano Zalis; Sara Lustigman
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).

Authors:  G R Nemerow; R Wolfert; M E McNaughton; N R Cooper
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

3.  Erythrocyte-binding antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent and -independent pathways.

Authors:  Manoj T Duraisingh; Alexander G Maier; Tony Triglia; Alan F Cowman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

Review 4.  Structure-function relationships of complement receptor type 1.

Authors:  M Krych-Goldberg; J P Atkinson
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

5.  Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.

Authors:  G D Ross; J D Lambris; J A Cain; S L Newman
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

6.  Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for invasion of human erythrocytes.

Authors:  Manoj T Duraisingh; Tony Triglia; Stuart A Ralph; Julian C Rayner; John W Barnwell; Geoffrey I McFadden; Alan F Cowman
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

7.  A Plasmodium falciparum homologue of Plasmodium vivax reticulocyte binding protein (PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway.

Authors:  J C Rayner; E Vargas-Serrato; C S Huber; M R Galinski; J W Barnwell
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

8.  Complement receptor is an inhibitor of the complement cascade.

Authors:  K Iida; V Nussenzweig
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

9.  Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.

Authors:  M E Medof; K Iida; C Mold; V Nussenzweig
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

10.  Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.

Authors:  L B Klickstein; T J Bartow; V Miletic; L D Rabson; J A Smith; D T Fearon
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Authors:  Rosalynn L Ord; Marilis Rodriguez; Cheryl A Lobo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

Review 3.  Protection of host cells by complement regulators.

Authors:  Christoph Q Schmidt; John D Lambris; Daniel Ricklin
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

4.  Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor.

Authors:  Hyon Ju Park; Mara Guariento; Mateusz Maciejewski; Richard Hauhart; Wai-Hong Tham; Alan F Cowman; Christoph Q Schmidt; Haydyn D T Mertens; M Kathryn Liszewski; Dennis E Hourcade; Paul N Barlow; John P Atkinson
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

5.  Insights into Duffy binding-like domains through the crystal structure and function of the merozoite surface protein MSPDBL2 from Plasmodium falciparum.

Authors:  Anthony N Hodder; Peter E Czabotar; Alessandro D Uboldi; Oliver B Clarke; Clara S Lin; Julie Healer; Brian J Smith; Alan F Cowman
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

6.  Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.

Authors:  Nicholas T Y Lim; Markus J Harder; Alexander T Kennedy; Clara S Lin; Christopher Weir; Alan F Cowman; Melissa J Call; Christoph Q Schmidt; Wai-Hong Tham
Journal:  J Biol Chem       Date:  2015-08-31       Impact factor: 5.157

Review 7.  Red cell receptors as access points for malaria infection.

Authors:  Nichole D Salinas; Niraj H Tolia
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

8.  The merozoite surface protein 1 complex is a platform for binding to human erythrocytes by Plasmodium falciparum.

Authors:  Clara S Lin; Alessandro D Uboldi; Danushka Marapana; Peter E Czabotar; Christian Epp; Hermann Bujard; Nicole L Taylor; Matthew A Perugini; Anthony N Hodder; Alan F Cowman
Journal:  J Biol Chem       Date:  2014-07-29       Impact factor: 5.157

9.  Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax.

Authors:  Jakub Gruszczyk; Usheer Kanjee; Li-Jin Chan; Sébastien Menant; Benoit Malleret; Nicholas T Y Lim; Christoph Q Schmidt; Yee-Foong Mok; Kai-Min Lin; Richard D Pearson; Gabriel Rangel; Brian J Smith; Melissa J Call; Michael P Weekes; Michael D W Griffin; James M Murphy; Jonathan Abraham; Kanlaya Sriprawat; Maria J Menezes; Marcelo U Ferreira; Bruce Russell; Laurent Renia; Manoj T Duraisingh; Wai-Hong Tham
Journal:  Science       Date:  2018-01-05       Impact factor: 47.728

10.  The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria.

Authors:  Linda Reiling; Jack S Richards; Freya J I Fowkes; Danny W Wilson; Watcharee Chokejindachai; Alyssa E Barry; Wai-Hong Tham; Janine Stubbs; Christine Langer; John Donelson; Pascal Michon; Livingstone Tavul; Brendan S Crabb; Peter M Siba; Alan F Cowman; Ivo Mueller; James G Beeson
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.